Meeting

162nd ACNFP Meeting

Last updated: 12 December 2023

View as PDF

Executive Summary

The 162nd meeting was held for two days allowing consideration of a number of returning applications in addition to new applications. Two returning applications Calcidiol and Dried Miracle Berry under agenda items 3 and 12, respectively, were postponed for the next available meeting due to meeting time constraints.
The Committee reviewed further information supplied by the applicant for Schizochytrium sp. Oil rich in DHA and EPA and agreed that they could complete their review. A draft Committee Advice document was discussed and will be finalised by Chair’s action.
The Committee reviewed further information supplied by the applicant for Cellobiose and requested further information on the production process, the method of analyses for residual proteins and allergenicity. The Committee reviewed the draft Committee Advice Document and identified areas for the Secretariat to amend. Members further input on the document would be sought via correspondence.
The Committee reviewed further information supplied by the applicant for Corn Protein and advised the Secretariat to seek further information on production process and composition.
Regarding novel food applications olive fruit dry extract standardized in hydroxytyrosol and Magnesium-L-threonate, the applicant’s responses, following the Secretariat’s requests for further information, were reviewed and considered sufficient. Draft Committee Advice Documents would be reviewed at the next available meeting.
The Committee reviewed a new application for Vitamin D2 Mushroom Powder for the first time and advised the Secretariat to seek further information on the production process, composition, stability, the methods of analyses for microbial contaminants and allergenicity.
The Committee reviewed three new Human Milk Oligosaccharide (HMO) applications from the same applicant: 2'-Fucosyllactose (2'-FL), 3'-Sialyllactose sodium salt (3'-SL) and 6'-Sialyllactose sodium salt (6'-SL). Members requested further information on identity, compositional and stability data the specifications, toxicological information and the production process. A draft Committee Advice Document was prepared for these applications as a trial new way of working and preliminary areas for the Secretariat to amend were identified.
The Committee reviewed a new application for Clostridium butyricum and requested further information on the identity and characterisation of the bacterial strain, the production process, proposed uses, toxicological information and further consideration for vulnerable groups.
The Secretariat provided Members with an update of the work of the joint COT and ACNFP subcommittee on cannabidiol (CBD) and hemp derived products. The findings of the subgroup and how these would influence the novel food assessment of the CBD dossiers was discussed. Along with consideration of the wider cross cutting questions on CBD that need to be considered and addressed in the assessment of the novel food applications.
The Committee reviewed the first of the CBD applications following review of the available toxicological data for >98% pure CBD by the ACNFP/COT subgroup. An approach for managing CBD dossiers following the Subgroup review was identified. Members reviewed the draft Committee Advice Document for the application and identified areas for the Secretariat to amend. The learning from this dossier will also be applied to the other two CBD dossiers, which while on the agenda, were not discussed in detail.
The Committee agreed that the 2022 ACNFP Annual Report is accurate, pending minor adjustments and clearance by Chair’s action would be sought with publication to follow.